Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
Official title: A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-09-18
Completion Date
2026-03
Last Updated
2026-03-19
Healthy Volunteers
Yes
Interventions
LY3537031
Administered SC
Locations (4)
Omega Research Orlando LLC
Orlando, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
New Zealand Clinical Research Christchurch
Christchurch, New Zealand